{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:45:58Z","timestamp":1791463558702,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministery of the University and Research","award":["Department of Excellence 2023-2027"],"award-info":[{"award-number":["Department of Excellence 2023-2027"]}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21853"],"award-info":[{"award-number":["21853"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14902-6","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:45:25Z","timestamp":1761119125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cephalomannine as in vitro and in vivo anticancer agent in mesothelioma cells: mechanisms of action"],"prefix":"10.1186","volume":"25","author":[{"given":"Federica","family":"Morani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Dell\u2019Anno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Daga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Doccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Bisceglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Gemignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"14902_CR1","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s10637-020-01040-y","volume":"39","author":"I Dell\u2019Anno","year":"2021","unstructured":"Dell\u2019Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, et al. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma. Invest New Drugs. 2021;39:644\u201357.","journal-title":"Invest New Drugs"},{"key":"14902_CR2","doi-asserted-by":"crossref","unstructured":"Dell\u2019Anno I, Melani A, Martin SA, Barbarino M, Silvestri R, Cipollini M, et al. A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma. Cancers (Basel). 2022;14.","DOI":"10.3390\/cancers14102527"},{"key":"14902_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/1099-0801(200012)14:8<516::AID-BMC15>3.0.CO;2-9","volume":"14","author":"T Mroczek","year":"2000","unstructured":"Mroczek T, Glowniak K, Hajnos M. Screening for pharmaceutically important taxoids in Taxus baccata var. Aurea corr. with CC\/SPE\/HPLC-PDA procedure. Biomed Chromatogr. 2000;14:516\u201329.","journal-title":"Biomed Chromatogr"},{"key":"14902_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10495-022-01750-z","volume":"27","author":"S Zhao","year":"2022","unstructured":"Zhao S, Tang Y, Wang R, Najafi M. Mechanisms of cancer cell death induction by paclitaxel: an updated review. Apoptosis. 2022;27:647\u201367.","journal-title":"Apoptosis"},{"key":"14902_CR5","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA. How taxol\/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677\u201381.","journal-title":"Mol Biol Cell"},{"key":"14902_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1091\/mbc.7.10.1547","volume":"7","author":"JC Waters","year":"1996","unstructured":"Waters JC, Mitchison TJ, Rieder CL, Salmon ED. The kinetochore microtubule minus-end disassembly associated with poleward flux produces a force that can do work. Mol Biol Cell. 1996;7:1547\u201358.","journal-title":"Mol Biol Cell"},{"key":"14902_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1083\/jcb.141.5.1181","volume":"141","author":"JC Waters","year":"1998","unstructured":"Waters JC, Chen RH, Murray AW, Salmon ED. Localization of Mad2 to kinetochores depends on microtubule attachment, not tension. J Cell Biol. 1998;141:1181\u201391.","journal-title":"J Cell Biol"},{"key":"14902_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253\u201365.","journal-title":"Nat Rev Cancer"},{"key":"14902_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245986","author":"J Gallego-Jara","year":"2020","unstructured":"Gallego-Jara J, Lozano-Terol G, Sola-Mart\u00ednez RA, C\u00e1novas-D\u00edaz M, de Diego Puente T. A compressive review about Taxol\u00ae: history and future challenges. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25245986.","journal-title":"Molecules"},{"key":"14902_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s13273-020-00093-7","volume":"16","author":"M Li","year":"2020","unstructured":"Li M, Yin L, Wu L, Zhu Y, Wang X. Paclitaxel inhibits proliferation and promotes apoptosis through regulation ROS and endoplasmic reticulum stress in osteosarcoma cell. Mol Cell Toxicol. 2020;16:377\u201384.","journal-title":"Mol Cell Toxicol"},{"key":"14902_CR11","first-page":"8289","volume":"17","author":"X Ren","year":"2018","unstructured":"Ren X, Zhao B, Chang H, Xiao M, Wu Y, Liu Y. Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT\/MAPK signaling pathway in canine mammary gland tumor cells. Mol Med Rep. 2018;17:8289\u201399.","journal-title":"Mol Med Rep"},{"key":"14902_CR12","doi-asserted-by":"publisher","first-page":"14094","DOI":"10.1073\/pnas.93.24.14094","volume":"93","author":"T Strobel","year":"1996","unstructured":"Strobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA. 1996;93:14094\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"14902_CR13","doi-asserted-by":"publisher","first-page":"6906","DOI":"10.1158\/0008-5472.CAN-09-0540","volume":"69","author":"C Ferlini","year":"2009","unstructured":"Ferlini C, Cicchillitti L, Raspaglio G, Bartollino S, Cimitan S, Bertucci C, et al. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009;69:6906\u201314.","journal-title":"Cancer Res"},{"key":"14902_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00018-018-2954-1","volume":"76","author":"J Miku\u0142a-Pietrasik","year":"2019","unstructured":"Miku\u0142a-Pietrasik J, Witucka A, Paku\u0142a M, Uruski P, Begier-Krasi\u0144ska B, Niklas A, et al. Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells. Cell Mol Life Sci. 2019;76:681\u201397.","journal-title":"Cell Mol Life Sci"},{"key":"14902_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.chemosphere.2016.11.065","volume":"169","author":"M Yang","year":"2017","unstructured":"Yang M, Wang B, Gao J, Zhang Y, Xu W, Tao L. Spinosad induces programmed cell death involves mitochondrial dysfunction and cytochrome C release in Spodoptera frugiperda Sf9 cells. Chemosphere. 2017;169:155\u201361.","journal-title":"Chemosphere"},{"key":"14902_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00041","volume":"3","author":"DH Suh","year":"2013","unstructured":"Suh DH, Kim M-K, Kim HS, Chung HH, Song YS. Mitochondrial permeability transition pore as a selective target for anti-cancer therapy. Front Oncol. 2013;3:41.","journal-title":"Front Oncol"},{"key":"14902_CR17","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3389\/fimmu.2019.01108","volume":"10","author":"S Son","year":"2019","unstructured":"Son S, Shim D-W, Hwang I, Park J-H, Yu J-W. Chemotherapeutic agent paclitaxel mediates priming of NLRP3 inflammasome activation. Front Immunol. 2019;10:1108.","journal-title":"Front Immunol"},{"key":"14902_CR18","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jtho.2023.01.095","volume":"18","author":"J Huang","year":"2023","unstructured":"Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18:792\u2013802.","journal-title":"J Thorac Oncol"},{"key":"14902_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5090\/kjtcs.2018.51.1.35","volume":"51","author":"B-S Na","year":"2018","unstructured":"Na B-S, Kim JS, Hyun K, Park IK, Kang CH, Kim YT. Outcomes of the multimodal treatment of malignant pleural mesiothelioma: the role of surgery. Korean J Thorac Cardiovasc Surg. 2018;51:35\u201340.","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"14902_CR20","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"14902_CR21","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet"},{"key":"14902_CR22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12935-024-03400-7","volume":"24","author":"I Dell\u2019Anno","year":"2024","unstructured":"Dell\u2019Anno I, Morani F, Patergnani S, Daga A, Pinton P, Giorgi C, et al. Thonzonium bromide inhibits progression of malignant pleural mesothelioma through regulation of ERK1\/2 and p38 pathways and mitochondrial uncoupling. Cancer Cell Int. 2024;24:226.","journal-title":"Cancer Cell Int"},{"key":"14902_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41420-020-0250-y","volume":"6","author":"S Doccini","year":"2020","unstructured":"Doccini S, Morani F, Nesti C, Pezzini F, Calza G, Soliymani R, et al. Proteomic and functional analyses in disease models reveal CLN5 protein involvement in mitochondrial dysfunction. Cell Death Discov. 2020;6:18.","journal-title":"Cell Death Discov"},{"key":"14902_CR24","doi-asserted-by":"publisher","first-page":"11878","DOI":"10.1038\/s41598-019-48047-x","volume":"9","author":"F Morani","year":"2019","unstructured":"Morani F, Doccini S, Sirica R, Paterno M, Pezzini F, Ricca I, et al. Functional transcriptome analysis in ARSACS KO cell model reveals a role of sacsin in autophagy. Sci Rep. 2019;9:11878.","journal-title":"Sci Rep"},{"key":"14902_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052738","author":"F Morani","year":"2021","unstructured":"Morani F, Bisceglia L, Rosini G, Mutti L, Melaiu O, Landi S, et al. Identification of overexpressed genes in malignant pleural mesothelioma. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22052738.","journal-title":"Int J Mol Sci"},{"key":"14902_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1124\/dmd.107.018242","volume":"36","author":"J-W Zhang","year":"2008","unstructured":"Zhang J-W, Ge G-B, Liu Y, Wang L-M, Liu X-B, Zhang Y-Y, et al. Taxane\u2019s substituents at C3\u2019 affect its regioselective metabolism: different in vitro metabolism of cephalomannine and paclitaxel. Drug Metab Dispos. 2008;36:418\u201326.","journal-title":"Drug Metab Dispos"},{"key":"14902_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.critrevonc.2006.09.006","volume":"61","author":"J Spratlin","year":"2007","unstructured":"Spratlin J, Sawyer MB. Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol. 2007;61:222\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"14902_CR28","doi-asserted-by":"publisher","DOI":"10.2198\/jelectroph.62.17","author":"ZKT Qiao","year":"2018","unstructured":"Qiao ZKT. Identification of cephalomannine as a drug candidate for glioblastoma via high-throughput drug screening. J Electrophoresis. 2018. https:\/\/doi.org\/10.2198\/jelectroph.62.17.","journal-title":"J Electrophoresis"},{"key":"14902_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2024.102577","volume":"91","author":"S An","year":"2024","unstructured":"An S, Xu X, Bao Y, Su F, Jiang Y. Cephalomannine reduces radiotherapy resistance in non-small cell lung cancer cells by blocking the \u03b2-catenin-BMP2 signaling pathway. Tissue Cell. 2024;91:102577.","journal-title":"Tissue Cell"},{"key":"14902_CR30","unstructured":"EMA. EPAR_abraxane. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abraxane."},{"key":"14902_CR31","unstructured":"EMA. EPAR_paxenir. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pazenir."},{"key":"14902_CR32","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3389\/fphar.2019.01210","volume":"10","author":"M Herrero Fernandez","year":"2019","unstructured":"Herrero Fernandez M, Molina Villaverde R, Arroyo Yustos M, Navarro Exp\u00f3sito F, Lopez Gonzalez JL, Luque Infantes MR, et al. The off-label use of antineoplastics in oncology is limited but has notable scientific support in a university hospital setting. Front Pharmacol. 2019;10:1210.","journal-title":"Front Pharmacol"},{"key":"14902_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100604","volume":"8","author":"G Zarkavelis","year":"2023","unstructured":"Zarkavelis G, Amylidi AL, Verbaanderd C, Cherny NI, Metaxas Y, de Vries EGE, et al. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. ESMO Open. 2023;8:100604.","journal-title":"ESMO Open"},{"key":"14902_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33:129\u201342.","journal-title":"Ann Oncol"},{"key":"14902_CR35","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jtcvs.2019.12.076","volume":"160","author":"N-Q Chu","year":"2020","unstructured":"Chu N-Q, Liu R, Colby A, de Forcrand C, Padera RF, Grinstaff MW, et al. Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts. J Thorac Cardiovasc Surg. 2020;160:e159\u201368.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"14902_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115678","volume":"214","author":"V Cocc\u00e8","year":"2023","unstructured":"Cocc\u00e8 V, Bonelli M, La Monica S, Alfieri R, Doneda L, Martegani E, et al. Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma. Biochem Pharmacol. 2023;214:115678.","journal-title":"Biochem Pharmacol"},{"key":"14902_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/rcr2.145","volume":"4","author":"O Kanai","year":"2016","unstructured":"Kanai O, Fujita K, Nakatani K, Mio T. Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma. Respirol Case Rep. 2016;4:28\u201331.","journal-title":"Respirol Case Rep"},{"key":"14902_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062907","volume":"12","author":"JP van Kooten","year":"2022","unstructured":"van Kooten JP, Dietz MV, Guchelaar NAD, Brandt-Kerkhof ARM, Koolen SLW, Burger JWA, et al. Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I\/II dose escalation and safety study-INTERACT MESO. BMJ Open. 2022;12:e062907.","journal-title":"BMJ Open"},{"key":"14902_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.suronc.2020.01.009","volume":"33","author":"PH Sugarbaker","year":"2020","unstructured":"Sugarbaker PH, Stuart OA. Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series Surg Oncol. 2020;33:96\u20139.","journal-title":"A case series Surg Oncol"},{"key":"14902_CR40","first-page":"322","volume":"28","author":"K Takeuchi","year":"2007","unstructured":"Takeuchi K, Fujimoto M, Tsujino T, Takeda Y, Yoshida S. Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel. Eur J Gynaecol Oncol. 2007;28:322\u20133.","journal-title":"Eur J Gynaecol Oncol"},{"key":"14902_CR41","doi-asserted-by":"publisher","first-page":"1157306","DOI":"10.3389\/fphar.2023.1157306","volume":"14","author":"M Sousa-Pimenta","year":"2023","unstructured":"Sousa-Pimenta M, Estevinho LM, Szopa A, Basit M, Khan K, Armaghan M, et al. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. Front Pharmacol. 2023;14:1157306.","journal-title":"Front Pharmacol"},{"key":"14902_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0378-5173(01)00986-3","volume":"235","author":"AK Singla","year":"2002","unstructured":"Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235:179\u201392.","journal-title":"Int J Pharm"},{"key":"14902_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0928-0987(00)00153-6","volume":"12","author":"JH Schellens","year":"2000","unstructured":"Schellens JH, Malingr\u00e9 MM, Kruijtzer CM, Bardelmeijer HA, van Tellingen O, Schinkel AH, et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci. 2000;12:103\u201310.","journal-title":"Eur J Pharm Sci"},{"key":"14902_CR44","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1124\/dmd.106.012153","volume":"34","author":"R Frapolli","year":"2006","unstructured":"Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, et al. Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. Drug Metab Dispos. 2006;34:2028\u201335.","journal-title":"Drug Metab Dispos"},{"key":"14902_CR45","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.2174\/1389557523666230210145150","volume":"23","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhao F, Wang Q, Zhao Q, Hou G, Meng Q. Current perspectives on Paclitaxel: focus on its production, delivery and combination therapy. Mini Rev Med Chem. 2023;23:1780\u201396.","journal-title":"Mini Rev Med Chem"},{"key":"14902_CR46","doi-asserted-by":"publisher","first-page":"e1323","DOI":"10.1016\/j.clbc.2018.07.010","volume":"18","author":"N Marschner","year":"2018","unstructured":"Marschner N, Salat C, S\u00f6ling U, Hansen R, Grebhardt S, Harde J, et al. Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel. Clin Breast Cancer. 2018;18:e1323\u201337.","journal-title":"Clin Breast Cancer"},{"key":"14902_CR47","doi-asserted-by":"publisher","first-page":"9430952","DOI":"10.1155\/2022\/9430952","volume":"2022","author":"Q Guo","year":"2022","unstructured":"Guo Q, Zhang H, Li X, Quan X. Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer. Biomed Res Int. 2022;2022:9430952.","journal-title":"Biomed Res Int"},{"key":"14902_CR48","doi-asserted-by":"crossref","unstructured":"Ni\u017enansk\u00fd \u013d, Osinov\u00e1 D, Kuruc R, Hengerics Szab\u00f3 A, Sz\u00f3r\u00e1dov\u00e1 A, Mas\u00e1r M, et al. Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms232415619"},{"key":"14902_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143325","author":"NN Chmielewski","year":"2022","unstructured":"Chmielewski NN, Limoli CL. Sex differences in taxane toxicities. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14143325.","journal-title":"Cancers (Basel)"},{"key":"14902_CR50","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1021\/jm9604080","volume":"39","author":"I Ojima","year":"1996","unstructured":"Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, et al. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem. 1996;39:3889\u201396.","journal-title":"J Med Chem"},{"key":"14902_CR51","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1016\/S0968-0896(03)00495-4","volume":"11","author":"H Mastalerz","year":"2003","unstructured":"Mastalerz H, Cook D, Fairchild CR, Hansel S, Johnson W, Kadow JF, et al. The discovery of BMS-275183: an orally efficacious novel taxane. Bioorg Med Chem. 2003;11:4315\u201323.","journal-title":"Bioorg Med Chem"},{"issue":"23","key":"14902_CR52","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1016\/j.bmcl.2005.08.066","volume":"15","author":"L Barboni","year":"2005","unstructured":"Barboni L, Ballini R, Giarlo G, Appendino G, Fontana G, Bombardelli E. Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390. Bioorg Med Chem Lett. 2005;15(23):5182\u20136.","journal-title":"Bioorg Med Chem Lett"},{"key":"14902_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00280-006-0362-y","volume":"60","author":"AC Lockhart","year":"2007","unstructured":"Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, et al. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. Cancer Chemother Pharmacol. 2007;60:203\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"14902_CR54","first-page":"329","volume":"15","author":"D Sano","year":"2006","unstructured":"Sano D, Matsuda H, Ishiguro Y, Nishimura G, Kawakami M, Tsukuda M. Antitumor effects of IDN5109 on head and neck squamous cell carcinoma. Oncol Rep. 2006;15:329\u201334.","journal-title":"Oncol Rep"},{"key":"14902_CR55","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-06-2875","volume":"13","author":"LE Br\u00f6ker","year":"2007","unstructured":"Br\u00f6ker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, et al. A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin Cancer Res. 2007;13:3906\u201312.","journal-title":"Clin Cancer Res"},{"key":"14902_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1254\/jphs.FP0040603","volume":"97","author":"R Taniguchi","year":"2005","unstructured":"Taniguchi R, Kumai T, Matsumoto N, Watanabe M, Kamio K, Suzuki S, et al. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci. 2005;97:83\u201390.","journal-title":"J Pharmacol Sci"},{"key":"14902_CR57","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S0090-9556(25)06829-1","volume":"23","author":"CD Anderson","year":"1995","unstructured":"Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK, Walle T. Dexamethasone induction of taxol metabolism in the rat. Drug Metab Dispos. 1995;23:1286\u201390.","journal-title":"Drug Metab Dispos"},{"key":"14902_CR58","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/dmd.30.4.438","volume":"30","author":"T Cresteil","year":"2002","unstructured":"Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos. 2002;30:438\u201345.","journal-title":"Drug Metab Dispos"},{"key":"14902_CR59","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1016\/S0968-0896(01)00206-1","volume":"9","author":"Q Shi","year":"2001","unstructured":"Shi Q, Wang HK, Bastow KF, Tachibana Y, Chen K, Lee FY, et al. Antitumor agents 210. Synthesis and evaluation of taxoid-epipodophyllotoxin conjugates as novel cytotoxic agents. Bioorg Med Chem. 2001;9:2999\u20133004.","journal-title":"Bioorg Med Chem"},{"key":"14902_CR60","first-page":"489","volume":"13","author":"M Distefano","year":"1998","unstructured":"Distefano M, Scambia G, Ferlini C, Gallo D, De Vincenzo R, Filippini P, et al. Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cells. Anticancer Drug Des. 1998;13:489\u201399.","journal-title":"Anticancer Drug Des"},{"key":"14902_CR61","first-page":"297","volume":"2","author":"L Helson","year":"1993","unstructured":"Helson L. Cephalomannine and 10-deacetyltaxol cytotoxicity in human glial and neuroblastoma cell-lines. Int J Oncol. 1993;2:297\u20139.","journal-title":"Int J Oncol"},{"key":"14902_CR62","unstructured":"SK HL and A. Method for assessing sensitivity of tumor cells to cephalomannine and 10-deacetyltaxol. NaPro BioTherapeutics, Inc, assignee. 1997;U.S. paten:688, 517."},{"key":"14902_CR63","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1182\/blood-2007-02-073213","volume":"110","author":"K Janssen","year":"2007","unstructured":"Janssen K, Pohlmann S, J\u00e4nicke RU, Schulze-Osthoff K, Fischer U. Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood. 2007;110:3662\u201372.","journal-title":"Blood"},{"key":"14902_CR64","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0026-895X(24)13247-6","volume":"53","author":"NA Jones","year":"1998","unstructured":"Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol. 199<\/","journal-title":"Mol Pharmacol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14902-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14902-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14902-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:03:34Z","timestamp":1761123814000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14902-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14902"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14902-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in accordance with the National Regulation on Animal Research Resources and approved by the Review Board of the IRCCS Policlinico San Martino, Genoa, Italy, and Italian Ministry of Health (n\u00b0 462\/2020-PR). Moreover, all aspects of the study comply with the criteria established by the Declaration of Helsinki and with the relevant ethical regulations for animal research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1625"}}